Formosa Pharmaceuticals (台新藥) is a clinical stage biopharmaceutical company with primary focus in ophthalmology and oncology. Our flagship asset, APP13007 (Clobetasol Propionate ophthalmic suspension 0.05%) was recently approved by the US FDA (March, 2024) for the treatment of post-operative inflammation and pain following ocular surgery. In August, 2017, Formosa Pharmaceuticals completed the acquisition of Activus Pharma, based in Funabashi, Japan. With the acquisition of the Activus Pure Nanoparticle Technology (APNT) Platform, Formosa Pharmaceuticals enters the ophthalmology disease area with two late-preclinical assets and the goal of expanding the platform’s scope and application. APNT effectively reduces API particle size to improve dissolution and bioavailability without the drawbacks of heavy metal contamination other platforms often experience.
View Top Employees from Formosa Pharmaceuticals, Inc.Website | http://www.formosapharma.com/ |
Revenue | $4 million |
Employees | 12 (8 on RocketReach) |
Founded | 2010 |
Phone | +886 2 2755 7659 |
Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Biotechnology, Pharmaceuticals, Healthcare |
SIC | SIC Code 283 Companies, SIC Code 80 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Formosa Pharmaceuticals, Inc. employee's phone or email?
The Formosa Pharmaceuticals, Inc. annual revenue was $4 million in 2024.
8 people are employed at Formosa Pharmaceuticals, Inc..
Formosa Pharmaceuticals, Inc. is based in Taipei, Taipei City.
The NAICS codes for Formosa Pharmaceuticals, Inc. are [3254, 32, 325].
The SIC codes for Formosa Pharmaceuticals, Inc. are [283, 80, 28].